Author/Authors :
Astani Akram نويسنده Shahid Sadoughi University of Medical Sciences, Yazd, Iran AND Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany. Astani Akram , Kheirandish Mohammad Hassan نويسنده School of Medicine,Department of Genetics,Shahid Sadoughi University of Medical Sciences,Yazd,Iran , Rahmani Behnaz نويسنده Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , Zarei Jaliani Hossein نويسنده Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. , Mosaddegh Ahmad نويسنده Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Asadi Saghandi Abolghasem نويسنده Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract :
Background and Aims: Enzybiotics are probably the future line of weapons against drug resistant bacteria. They lyse bacteria with the new mechanisms with few likelihood of generating resistance. LasA, which is secreted from Pseudomonas strains degrades Staphylococcus aureus (S. aureus) cell wall and has the potential to use against drug resistant S. aureus infections.
Materials and Methods: Codon-optimized gene of the mature form of the LasA protein was ordered. The gene was double digested with NcoI and XhoI restriction enzymes and sub-cloned into pET28a(+) digested with the same enzymes. Recombinant construct was introduced into BL21 DE3 cell. Expression of the gene was induced by 0.2 mM isopropyl B-D-1-thiogalactopyranoside and recombinant protein was affinity purified by Ni-NTA mini-column. The staphylolytic activity of the recombinant LasA protein was evaluated on Methicillin-resistant S. aureus (MRSA) by disk diffusion.
Results: Fragment of the LasA gene encoding mature form of the LasA protein was introduced into pET28a(+) expression vector. C-terminal
his-tagged recombinant LasA protein was produced in BL21 DE3 E. coli cells. Over 50% purity has been achieved by affinity purification of the LasA protein from the total cell lysate. The yield of purified protein was 5.4 mg.l-1. Growth of MRSA was completely inhibited by dilutions of recombinant his-tagged LasA.
Conclusions: The present study shows that the mature form of the LasA can be expressed in E. coli BL21 DE3 cells. C-terminal his-tagged form of the mature LasA protein has staphylolytic activity against MRSA and so it can be a promising therapeutic agent.
